02294nas a2200349   4500000000100000008004100001260002300042653005700065653002900122100001300151700001500164700001400179700001200193700001300205700001100218700001400229700001800243700001200261700001000273700001600283700001500299700001100314700001300325700001500338700001600353245014900369856010700518300000600625490000600631520129300637022001401930       2022                            d  bF1000 Research Ltd10aGeneral Biochemistry, Genetics and Molecular Biology10aMedicine (miscellaneous)1 aWalker M1 aFreitas LT1 aHalder JB1 aBrack M1 aKeiser J1 aKing C1 aLevecke B1 aAi-Lian Lim Y1 aPieri O1 aSow D1 aStothard JR1 aWebster JP1 aZhou X1 aTerry RF1 aGuérin PJ1 aBasáñez M00aImproving anthelmintic treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of individual participant data  uhttps://wellcomeopenresearch.org/articles/7-5/v1/pdf?article_uuid=83cbdecb-eb2f-4e1b-a995-8a9ecfc95dc1  a50 v73 a<p>The Infectious Diseases Data Observatory (IDDO, https://www.iddo.org) has launched a clinical data platform for the collation, curation, standardisation and reuse of individual participant data (IPD) on treatments for two of the most globally important neglected tropical diseases (NTDs), schistosomiasis (SCH) and soil-transmitted helminthiases (STHs). This initiative aims to harness the power of data-sharing by facilitating collaborative joint analyses of pooled datasets to generate robust evidence on the efficacy and safety of anthelminthic treatment regimens. A crucial component of this endeavour has been the development of a Research Agenda to promote engagement with the SCH and STH research and disease control communities by highlighting key questions that could be tackled using data shared through the IDDO platform. Here, we give a contextual overview of the priority research themes articulated in the Research Agenda—a ‘living’ document hosted on the IDDO website—and describe the three-stage consultation process behind its development. We also discuss the sustainability and future directions of the platform, emphasising throughout the power and promise of ethical and equitable sharing and reuse of clinical data to support the elimination of NTDs.</p>
  a2398-502X